Literature DB >> 14584290

[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].

Eijiro Nagasaki1, Noriyuki Furuta, Eiji Shinozaki, Nahomi Tokutome, Yuko Mishima, Keisho Chin, Yasuhito Terui, Nobuyuki Mizunuma, Shunji Takahashi, Yoshinori Itoh, Noriko Usui, Kiyohiko Hatake.   

Abstract

A 55-year-old woman underwent breast-conserving surgery with irradiation for Stage IIB (T2 N1 M0) breast cancer of her right breast. Thereafter, she was treated orally with oral UFT and tamoxifen. Three years following surgery, she was diagnosed as having a non-Hodgkin's lymphoma. She underwent 6 cycles of EPOCH-G (etoposide, vincristine, adriamycin, cyclophosphamide, prednisolone, G-CSF) therapy, and obtained complete remission. Two years later, her neck and inguinal lymph nodes were swollen. Biopsy confirmed the relapse of NHL. She underwent salvage chemotherapies of MST-16, carboplatin, IVAC, and CPT-11, but the disease was refractory. In May 2000, bilateral pleural effusion was detected. Cytomorphologically, the pleural fluid specimen showed both atypical lymphoid cells and adenocarcinoma cells simultaneously. Existence of double cancer in the pleural effusion has not been reported, suggesting that this case is rare.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584290

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  How to prioritize treatment in dual malignancy: A case report of patient with non-Hodgkin lymphoma and breast cancer.

Authors:  Alvi Chomariyati; Muhammad Noor Diansyah; Putu Niken Ayu Amrita; Pradana Zaky Romadhon; Siprianus Ugroseno Yudho Bintoro; Ami Ashariati; Merlyna Savitri
Journal:  Ann Med Surg (Lond)       Date:  2022-07-31

2.  A rare case of non-invasive ductal carcinoma of the breast coexisting with follicular lymphoma: A case report with a review of the literature.

Authors:  Mikako Tamaoki; Yoshinori Nio; Kazuhiko Tsuboi; Marika Nio; Masashi Tamaoki; Riruke Maruyama
Journal:  Oncol Lett       Date:  2014-02-14       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.